Variation in permissibility across vaccine product-specific policies, 30 September 2021
| Vaccine* | Recommended for some or all | Permitted | Permitted with qualifications | Not recommended but with exceptions | Not recommended | Total | |||||
| n | % | n | % | n | % | n | % | n | % | n | |
| Oxford/AstraZeneca | 8 | 9.6 | 10 | 12.2 | 20 | 24.1 | 11 | 13.3 | 34 | 41.0 | 83 |
| Pfizer/ BioNTech | 45 | 442.1 | 33 | 30.8 | 17 | 15.9 | 6 | 5.6 | 6 | 5.6 | 107 |
| Moderna | 34 | 46.6 | 24 | 32.9 | 9 | 12.3 | 3 | 4.1 | 3 | 4.1 | 73 |
| Sinopharm | 6 | 23.1 | 4 | 15.4 | 6 | 23.1 | 2 | 7.7 | 8 | 30.8 | 26 |
| Gamaleya | 2 | 10.0 | 2 | 10.0 | 1 | 5.0 | 0 | 0.0 | 15 | 75.0 | 20 |
| Sinovac | 8 | 44.4 | 1 | 5.6 | 4 | 22.2 | 0 | 0.0 | 5 | 27.8 | 18 |
| Johnson & Johnson | 7 | 18.0 | 8 | 20.5 | 10 | 25.6 | 3 | 7.7 | 11 | 28.2 | 39 |
| Bharat Biotech Covaxin | 1 | 50.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 50.0 | 2 |
| CanSino Biologics Convidecia | 2 | 40.0 | 1 | 20.0 | 1 | 20.0 | 0 | 0.0 | 1 | 20.0 | 5 |
| Non-specific | 24 | 22.4 | 36 | 33.6 | 11 | 10.3 | 8 | 7.5 | 28 | 26.2 | 107 |
*Includes vaccines where product-specific guidance on the use of the vaccine in pregnancy was available for more than one country/territory.